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LaVIISWA trial team members are in Appendix [1](#pim12506-app-0001){ref-type="app"}.

1. INTRODUCTION {#pim12506-sec-0001}
===============

Helminths have a small range of antigens that are strikingly homologous to common allergens.[1](#pim12506-bib-0001){ref-type="ref"} These antigens induce immunoglobulin (Ig) E‐mediated effector responses important for protection against helminth infection.[2](#pim12506-bib-0002){ref-type="ref"}, [3](#pim12506-bib-0003){ref-type="ref"} To survive in the host, helminths modulate this atopic pathway, and this may have a bystander protective effect against allergy‐related disease (ARD).[4](#pim12506-bib-0004){ref-type="ref"} While several animal and human studies provide compelling evidence of this protection,[5](#pim12506-bib-0005){ref-type="ref"}, [6](#pim12506-bib-0006){ref-type="ref"} others suggest that in some circumstances helminths may actually promote enhanced responses to allergens.[7](#pim12506-bib-0007){ref-type="ref"}, [8](#pim12506-bib-0008){ref-type="ref"}

Mechanisms underlying helminth‐allergy associations in low‐income countries (LICs) are not fully understood. Hypothesized pathways that underpin these associations are shown in Figure [1](#pim12506-fig-0001){ref-type="fig"}. Helminth‐induced cytokine and antibody profiles may influence allergic responses and consequently epidemiological trends pertaining to ARDs.[5](#pim12506-bib-0005){ref-type="ref"}, [9](#pim12506-bib-0009){ref-type="ref"} Both helminth‐ and allergen‐specific immune responses are characterized by elevated Th2‐type responses (interleukin \[IL\]‐4, IL‐5 and IL‐13).[10](#pim12506-bib-0010){ref-type="ref"}, [11](#pim12506-bib-0011){ref-type="ref"} Helminths, unlike allergens, further induce strong immunoregulation epitomized by IL‐10 production.[12](#pim12506-bib-0012){ref-type="ref"} Typically, these cytokines influence the profile of antibodies involved in helminth infection and allergy. Helminth‐induced IL‐10 may drive immunoglobulin class switching to IgG4[13](#pim12506-bib-0013){ref-type="ref"}, [14](#pim12506-bib-0014){ref-type="ref"} which, akin to the Th2 cytokine‐induced[15](#pim12506-bib-0015){ref-type="ref"} polyclonally stimulated IgE, may inhibit development of allergen‐specific effector responses,[5](#pim12506-bib-0005){ref-type="ref"}, [16](#pim12506-bib-0016){ref-type="ref"} leading to inverse helminth‐allergy associations. Conversely, helminth‐induced protein‐specific IgE may promote strong, cross‐reactive helminth‐ and allergen‐specific responses, resulting in positive helminth‐allergy associations.[17](#pim12506-bib-0017){ref-type="ref"}, [18](#pim12506-bib-0018){ref-type="ref"}

![We hypothesize that the Th2 cytokine‐induced *Sm*‐specific IgE promotes potent, *Sm*‐specific, atopic effector responses and *Sm* elimination from the host, and also cross‐reactive responses to some allergens, resulting in positive *Sm*‐allergy associations. By contrast, *Sm‐*specific IL‐10, IgG4 and/or nonspecific polyclonally stimulated IgE inhibit these allergy‐related outcomes. White and shaded arrows denote promotion and inhibition, respectively](PIM-40-na-g001){#pim12506-fig-0001}

Emerging epidemiological data on helminth‐allergy associations in Uganda reflect the complex interaction between helminths and allergens: while observational analyses in a birth cohort suggested a protective effect of childhood and maternal helminths against childhood eczema[19](#pim12506-bib-0019){ref-type="ref"} that was reversed by maternal anthelminthic treatment,[20](#pim12506-bib-0020){ref-type="ref"} we recently reported positive helminth‐allergy associations in a survey conducted in the *Schistosoma mansoni* (*Sm*)‐endemic Lake Victoria islands, albeit against a backdrop of low ARD prevalence.[21](#pim12506-bib-0021){ref-type="ref"} To establish how *Sm‐*induced cytokine and antibody profiles underpinned helminth‐allergy associations in the above survey, we here describe an assessment of *Sm‐*specific cytokine profiles, as well as total, allergen‐ and *Sm‐*specific IgE and IgG4 profiles, and their relationship with *Sm* infection status, wheeze and atopy.

2. METHODS {#pim12506-sec-0002}
==========

2.1. Study population {#pim12506-sec-0003}
---------------------

Samples were collected during the baseline household survey preceding a cluster‐randomized trial of standard vs intensive anthelminthic intervention (the Lake Victoria Island Intervention Study on Worms and Allergy‐related diseases, LaVIISWA; ISRCTN47196031) described elsewhere.[21](#pim12506-bib-0021){ref-type="ref"}, [22](#pim12506-bib-0022){ref-type="ref"} Briefly, each consenting LaVIISWA participant completed a questionnaire, provided blood, urine and stool and underwent skin prick testing (SPT). Primary allergy‐related outcomes were reported wheeze in the previous 12 months and atopy. Wheeze is widely used as a surrogate for asthma in epidemiological studies[23](#pim12506-bib-0023){ref-type="ref"} and was assessed for all ages using the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire. Such symptom questionnaires have been identified as the best way to estimate asthma prevalence in epidemiological studies.[23](#pim12506-bib-0023){ref-type="ref"} The ISAAC questionnaire was used to ask participants (or their caregivers) if they had ever wheezed and if so, if they had wheezed in the last 12 months. Details on aetiology were not collected. Atopy was defined as (i) SPT reactivity to any of *Dermatophagoides* mix, *Blomia tropicalis* or German cockroach (*Blattella germanica*) \[ALK‐Abelló; supplied by Laboratory Specialities Ltd., South Africa\], and (ii) detectable IgE response (\>312 ng/mL by ELISA[21](#pim12506-bib-0021){ref-type="ref"}) to *Dermatophagoides pteronyssinus* \[hereinafter "house dust mite (HDM)"\] and/or German cockroach whole allergen extracts (Greer Labs, USA).

Ethics committees of Uganda Virus Research Institute, London School of Hygiene and Tropical Medicine and Uganda National Council for Science and Technology approved the study.

2.2. Laboratory methods {#pim12506-sec-0004}
-----------------------

Two slides from one stool sample per individual were independently examined by different technicians for *Sm* eggs using the Kato‐Katz method.[24](#pim12506-bib-0024){ref-type="ref"}

We assessed IFN‐γ (Th1‐type), IL‐5, IL‐13 (Th2‐type) and IL‐10 (regulatory) levels by ELISA using supernatants from six‐day whole blood cultures stimulated with *Schistosoma* worm (SWA) and egg antigens (SEA), as previously described.[25](#pim12506-bib-0025){ref-type="ref"} Briefly, heparinized blood was diluted with RPMI 1640 medium (Life technologies, UK) supplemented with penicillin, streptomycin, glutamine and Hepes buffer (all from Life technologies, UK), plated in 96‐well culture plates and stimulated (at 37°C, 5% CO~2~) with 10 μg/mL SWA or SEA (provided by Professor Mike Doenhoff, University of Nottingham) or mitogen (phytohaemagglutinin, PHA, Sigma, UK), or left unstimulated. Supernatants were harvested on day six and stored at −80°C until analysis. Cytokine levels in supernatants were measured by ELISA (Becton Dickinson, USA). The net response to each stimulus was calculated by subtracting the concentration in the unstimulated control well. Response values that were below the dynamic range of the assay and those that were negative after subtraction of the response in the unstimulated well were assigned a value of zero.

HDM and cockroach extract‐specific IgE and IgG4 were measured in plasma using an in‐house ELISA described previously.[20](#pim12506-bib-0020){ref-type="ref"} Briefly, MICROLON^®^ 96‐well plates (Greiner bio‐one, UK) were coated overnight at 4°C with 5 μg/mL HDM or cockroach allergens and twofold dilutions of human IgE (Calbiochem, Beeston, UK) or IgG4 (Sigma‐Aldrich) standards. Plates were blocked at room temperature (RT) with 1% skimmed milk and incubated overnight at 4°C with plasma samples diluted 1/20 (IgE assay) or 1/40 (IgG4 assay) with 10% foetal bovine serum in PBS‐Tween 20. Specific IgE or IgG4 was detected using biotinylated monoclonal mouse anti‐human IgE or IgG4 (BD Pharmingen^™^) and a streptavidin‐horseradish peroxidase conjugate (Mast Group Ltd, Bootle, UK). O‐phenylenediamine (Sigma‐Aldrich) was used as a substrate, and the reaction stopped with 2M sulphuric acid. Optical density values were measured at 490nm (reference wavelength 630nm) on a 96‐well plate ELISA reader. IgE or IgG4 concentrations (ng/mL) were interpolated from standard curves using a five‐parameter curve fit using Gen5 data collection and analysis software (BioTek Instruments Inc, Vermont, Winooski, USA). Total, SWA‐ and SEA‐specific IgE and IgG4 ELISAs were performed using similar in‐house procedures (detailed in this article\'s supporting information).

2.3. Statistical methods {#pim12506-sec-0005}
------------------------

Our hypothesized mode of action of *S. mansoni*‐induced cytokines and antibodies on allergy‐related outcomes is illustrated in Figure [1](#pim12506-fig-0001){ref-type="fig"}. Using STATA 13.1 (College Station, Texas, USA), we performed cross‐sectional analyses to assess whether *Sm* Kato‐Katz positivity and allergy‐related outcomes were associated with antibody and cytokine levels, using the "svy" command to allow for the non--self‐weighting cluster survey design. Raw cytokine and antibody responses were skewed, so log~10~ (concentration+1)‐transformed antibody and cytokine data were used in our regression models; we back‐transformed the results to obtain geometric mean ratios and 95% confidence intervals. Crude and age‐ and sex‐adjusted analyses were performed. Associations between antibody responses were estimated using Spearman\'s correlation coefficient (*r* ~s~). We used a 5% significance level for all analyses. *P* values quoted in the main text are from adjusted analyses.

3. RESULTS {#pim12506-sec-0006}
==========

Questionnaire data were obtained from 2316 participants.[22](#pim12506-bib-0022){ref-type="ref"} Their characteristics and those of participants for whom cytokine and antibody responses were assessed are shown in Table [1](#pim12506-tbl-0001){ref-type="table-wrap"}. Participants for whom cytokine (n = 407) and total antibody levels (n = 471) were assessed were a subset of participants who had allergen‐, SWA‐ and SEA‐specific antibody results (n = 2117). Cytokine responses were assessed using samples from 1‐ to 17‐year‐olds, to allow comparison with related cellular immunology studies in an urban birth cohort (data not shown). Allergen‐, SWA‐ and SEA‐specific responses were assessed in all survey participants that had sufficient plasma sample stored.

###### 

Characteristics of participants

  Characteristic                                                  Survey population (N = 2316), n/N (%)   Immunological measure, n/N (%)                      
  --------------------------------------------------------------- --------------------------------------- -------------------------------- ------------------ -----------------
  Age in years, median (IQR)                                      24 (8, 32)                              9 (6, 16)                        25 (10, 33)        19.5 (3, 31.25)
  Male sex                                                        1268/2316 (54.7)                        168/407 (41.3)                   1152/2117 (54.4)   225/471 (47.7)
  PZQ in last 12 mo                                               382/2255 (16.9)                         48/393 (12.2)                    368/2062 (17.8)    15/459 (15.5)
  Helminth infections                                                                                                                                         
  *S. mansoni* (KK)                                               1041/1996 (51.4)                        204/373 (54.7)                   1008/1882 (53.6)   184/428 (42.9)
  *S. mansoni* (urine CCA)                                        661/917 (72.0)                          94/128 (73.4)                    634/875 (72.5)     101/152 (66.5)
  *S. mansoni* intensity (KK)                                                                                                                                 
  Uninfected                                                      995/1996 (48.6)                         169/373 (45.3)                   874/1882 (46.4)    244/428 (57.0)
  Low                                                             429/1996 (21.0)                         77/373 (20.6)                    411/1882 (21.8)    70/428 (16.4)
  Moderate                                                        288/1996 (13.7)                         56/373 (15.0)                    279/1882 (14.8)    51/428 (11.9)
  Heavy                                                           324/1996 (16.6)                         71/373 (19.0)                    318/1882 (16.9)    63/428 (14.7)
  Any nematode infection[d](#pim12506-note-0006){ref-type="fn"}   788/2004 (39.3)                         129/373 (34.6)                   738/1889 (39.1)    87/428 (20.3)
  Allergy‐related outcomes                                                                                                                                    
  Wheeze in last 12 mo                                            107/2301 (4.7)                          14/404 (3.5)                     106/2103 (5.04)    58/468 (12.4)
  Atopy (SPT)                                                                                                                                                 
  Any                                                             404/1976 (19.1)                         78/372 (20.9)                    403/1961 (20.6)    135/448 (30.1)
  *Dermatophagoides*                                              190/1978 (9.0)                          33/372 (8.9)                     189/1963 (9.6)     61/448 (13.6)
  *Blomia*                                                        205/1976 (9.6)                          31/372 (8.3)                     204/1961 (10.4)    67/447 (14.9)
  Cockroach                                                       272/1977 (13.2)                         61/372 (16.4)                    272/1962 (13.9)    90/448 (20.1)
  Atopy (detectable asIgE)                                                                                                                                    
  Any                                                             1685/2117 (79.6)                        320/403 (79.4)                   1685/2117 (79.6)   358/471 (76.0)
  *Dermatophagoides*                                              1534/2115 (72.5)                        278/403 (68.9)                   1534/2115 (72.5)   326/471 (69.2)
  Cockroach                                                       886/2117 (41.9                          183/403 (45.4)                   886/2117 (41.9)    186/471 (39.5)

PZQ, Praziquantel treatment; KK, Kato‐Katz; CCA, circulating cathodic antigen; SPT, skin prick test; SWA, *Schistosoma* worm antigen; SEA, *Schistosoma* egg antigen; asIgE: allergen‐specific IgE.

Assessed using samples from 1‐ to 17‐year‐olds, to allow comparison with related cellular immunology studies in an urban birth cohort (data not shown here).

Assessed in all survey participants that had sufficient plasma sample stored.

Samples randomly selected from individuals with antigen‐specific antibody data.

Infection with any of *Ascaris lumbricoides, Trichuris trichiura (assessed by KK), Necator americanus, Strongyloides stercoralis (assessed by PCR)* and *Mansonella perstans (assessed by modified Knott\'s method)*.
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3.1. *S. mansoni‐*specific cytokines and allergy‐related outcomes {#pim12506-sec-0007}
-----------------------------------------------------------------

Individuals who tested positive for *Sm* by Kato‐Katz (SmKK+) had higher geometric mean concentrations of SWA‐specific type 2 and regulatory cytokines compared to SmKK‐ individuals (Table** ** [2](#pim12506-tbl-0002){ref-type="table-wrap"}), but this was statistically significant only for IL‐5 (*P* = .034). However, there was no dose‐response relationship with infection intensity (Table [S3](#pim12506-sup-0001){ref-type="supplementary-material"}A). SEA‐specific responses were similar between SmKK+ and SmKK‐ individuals.

###### 

Associations between *S. mansoni*‐specific cytokine levels and (i) *S. mansoni* infection status, (ii) reported wheeze and (iii) atopy (SPT reactivity and detectable allergen‐specific IgE)

                      Geometric mean[a](#pim12506-note-0008){ref-type="fn"}                                                                                           
  ------- ----------- ------------------------------------------------------- ----------------------- ------------------- ----------------------- ------------------- ------
  SWA     IFN‐γ       1.16                                                    1.13                    1.06 (0.86, 1.30)   .542                    1.05 (0.87, 1.28)   .531
  IL‐5    **14.92**   **49.47**                                               **1.43 (1.13, 1.81)**   **.005**            **1.32 (1.02, 1.71)**   **.034**            
  IL‐13   7.01        17.56                                                   1.20 (0.94, 1.54)       .132                1.15 (0.88, 1.48)       .282                
  IL‐10   3.99        11.58                                                   1.21 (0.97, 1.51)       .084                1.16 (0.91, 1.48)       .207                
  SEA     IFN‐γ       0.73                                                    0.56                    0.97 (0.81, 1.17)   .760                    0.98 (0.82, 1.18)   .884
  IL‐5    5.02        3.11                                                    0.84 (0.59, 1.19)       .320                0.84 (0.58, 1.19)       .319                
  IL‐13   2.25        1.95                                                    0.86 (0.71, 1.05)       .127                0.88 (0.73, 1.06)       .190                
  IL‐10   3.19        4.42                                                    0.93 (0.78, 1.13)       .486                0.93 (0.76, 1.13)       .477                

                     No wheeze n = 390   Wheeze n = 14                                                                                   
  ------- ---------- ------------------- ----------------------- ----------------------- ----------------------- ----------------------- ------------
  SWA     IFN‐γ      **1.27**            **0.23**                **0.60 (0.45, 0.80)**   **.001**                **0.57 (0.44, 0.76)**   **\<.001**
  IL‐5    29.12      27.59               1.29 (0.72, 2.33)       .373                    1.14 (0.63, 2.08)       .657                    
  IL‐13   11.75      9.78                1.26 (0.65, 2.45)       .465                    1.17 (0.58, 2.36)       .635                    
  IL‐10   **7.91**   **2.03**            **0.69 (0.47, 1.01)**   **.059**                **0.66 (0.43, 1.02)**   **.058**                
  SEA     IFN‐γ      0.66                0.33                    0.83 (0.66, 1.04)       .101                    0.83 (0.65, 1.05)       .121
  IL‐5    **4.37**   **1.20**            **0.52 (0.33, 0.83)**   **.007**                **0.51 (0.33, 0.79)**   **.004**                
  IL‐13   2.25       0.96                0.75 (0.44, 1.25)       .256                    0.76 (0.44, 1.33)       .327                    
  IL‐10   4.34       0.59                0.70 (0.35, 1.38)       .295                    0.71 (0.37, 1.36)       .291                    

                     SPT− n = 294   SPT+[c](#pim12506-note-0010){ref-type="fn"}n = 78                                                               
  ------- ---------- -------------- --------------------------------------------------- ------------------- ------------------- ------------------- ------
  SWA     IFN‐γ      1.03           1.73                                                1.15 (0.96, 1.36)   .115                1.13 (0.94, 1.34)   .178
  IL‐5    29.23      39.73          1.15 (0.86, 1.52)                                   .330                1.02 (0.75, 1.38)   .897                
  IL‐13   13.54      10.32          0.99 (0.72, 1.36)                                   .961                0.92 (0.67, 1.26)   .596                
  IL‐10   **6.79**   **12.00**      **1.25 (1.00, 1.55)**                               **.048**            1.21 (0.95, 1.54)   .126                
  SEA     IFN‐γ      0.55           0.99                                                1.11 (0.82, 1.51)   .493                1.13 (0.83, 1.52)   .423
  IL‐5    4.54       3.68           1.00 (0.70, 1.45)                                   .965                0.98 (0.67, 1.43)   .935                
  IL‐13   2.81       1.09           0.84 (0.56, 1.25)                                   .376                0.85 (0.58, 1.25)   .413                
  IL‐10   4.12       3.09           0.94 (0.76, 1.16)                                   .560                0.96 (0.75, 1.22)   .730                

                      Undetectable asIgE n = 83   Detectable asIgE[d](#pim12506-note-0011){ref-type="fn"}n = 320                                                                   
  ------- ----------- --------------------------- ---------------------------------------------------------------- ------------------- ----------------------- ------------------- ------
  SWA     IFN‐γ       1.73                        1.11                                                             0.87 (0.62, 1.24)   .444                    0.86 (0.60, 1.23)   .396
  IL‐5    **16.44**   **34.25**                   **1.43 (1.16, 1.75)**                                            **.001**            **1.32 (1.09, 1.61)**   **.006**            
  IL‐13   9.75        12.66                       1.09 (0.77, 1.55)                                                .599                1.04 (0.74, 1.47)       .806                
  IL‐10   **3.76**    **9.26**                    **1.34 (1.18, 1.51)**                                            **\<.001**          **1.30 (1.16, 1.46)**   **\<.001**          
  SEA     IFN‐γ       1.12                        0.56                                                             0.79 (0.56, 1.13)   .190                    0.79 (0.57, 1.11)   .176
  IL‐5    3.78        4.17                        1.13 (0.81, 1.58)                                                .459                1.12 (0.82, 1.54)       .450                
  IL‐13   2.21        2.21                        0.88 (0.65, 1.22)                                                .449                0.90 (0.67, 1.21)       .484                
  IL‐10   3.49        4.17                        1.05 (0.92, 1.21)                                                .424                1.06 (0.93, 1.21)       .382                

SmKK−, Kato‐Katz negative result (*S. mansoni*), single stool sample; SmKK+, Kato‐Katz positivity for *S. mansoni*, single stool sample; SPT, skin prick test; SWA, *Schistosoma* worm antigen; SEA, *Schistosoma* egg antigen; asIgE, allergen‐specific IgE; GMR, geometric mean ratio; 95% CI, 95% confidence interval. *P* values ≤.05 are highlighted in bold.

All cytokine concentrations in pg/mL.

Geometric mean ratios and 95% confidence intervals adjusted for the survey design.

SPT reactivity to any one of *Dermatophagoides* mix, *Blomia tropicalis* or *Blattella germanica*.

Detectable IgE to either *Dermatophagoides pteronyssinus* or *Blattella germanica*.

John Wiley & Sons, Ltd

Wheeze was inversely associated with SWA‐specific IFN‐γ (*P* \< .001) and IL‐10 (*P* = .058; Table** ** [2](#pim12506-tbl-0002){ref-type="table-wrap"}), and SWA‐specific IL‐10/IL‐5 and SEA‐specific IL‐10/IFN‐γ ratios (Table [S1](#pim12506-sup-0001){ref-type="supplementary-material"}). Wheezing individuals also had lower mean SEA‐specific cytokine responses, although statistical evidence for an inverse association was observed only for SEA‐specific IL‐5 (*P* = .004).

Conversely, there was a crude positive association between SPT positivity and SWA‐specific IL‐10 (*P* = .048; Table [2](#pim12506-tbl-0002){ref-type="table-wrap"}); and individuals with detectable allergen‐specific (as)IgE had higher SWA‐specific IL‐5 (*P* = .006) and IL‐10 responses (*P* \< .001; Table** ** [2](#pim12506-tbl-0002){ref-type="table-wrap"}) and higher SWA‐ and SEA‐specific IL‐10/IFN‐γ and IL‐5/IFN‐γ ratios (Table [S1](#pim12506-sup-0001){ref-type="supplementary-material"}).

3.2. Antibody responses, *S. mansoni* Kato‐Katz positivity and allergy {#pim12506-sec-0008}
----------------------------------------------------------------------

Kato‐Katz positivity was strongly positively associated with SWA‐ and SEA‐specific IgE and IgG4 (*P* \< .001), with HDM*‐*specific IgE (*P* = .006) and HDM*‐* and cockroach‐specific IgG4 (*P* \< .001; Table** ** [3](#pim12506-tbl-0003){ref-type="table-wrap"} and supplementary Figure [S1](#pim12506-sup-0001){ref-type="supplementary-material"}). However, correlations between *Sm* antigen‐specific antibodies and allergen‐specific antibodies were weak (*r* ~s~ \< .4, Table [S2](#pim12506-sup-0001){ref-type="supplementary-material"})**.**

###### 

Associations between antibody (IgE and IgG4) levels and Kato‐Katz positivity (*S. mansoni*), SPT reactivity and reported wheeze

                                               Geometric mean[a](#pim12506-note-0013){ref-type="fn"}                                                   
  ------------------------------- ------------ ------------------------------------------------------- ----------------------- ----------------------- ------------
  SWA                             IgE          **1080**                                                **2433**                **1.54 (1.28, 1.84)**   **\<.001**
  IgG4                            **4031**     **27 355**                                              **3.71 (3.14, 4.37)**   **\<.001**              
  SEA                             IgE          **1412**                                                **1833**                **1.32 (1.15, 1.52)**   **\<.001**
  IgG4                            **18 962**   **241 763**                                             **5.51 (4.55, 6.67)**   **\<.001**              
  House dust mite                 IgE          **0.782**                                               **10.678**              **1.25 (1.07, 1.45)**   **.006**
  IgG4                            **0.001**    **0.192**                                               **1.79 (1.51, 2.13)**   **\<.001**              
  IgG4/IgE ratio                  0.002        0.033                                                   1.18 (0.58, 2.41)       .629                    
  Cockroach                       IgE          18.8                                                    19.2                    1.00 (0.82, 1.22)       .989
  IgG4                            **0.002**    **0.292**                                               **1.50 (1.34, 1.68)**   **\<.001**              
  IgG4/IgE ratio                  0.001        0.027                                                   1.32 (0.94, 1.85)       .110                    
  Total IgE                       **969**      **3073**                                                **1.37 (1.22, 1.54)**   **\<.001**              
  Total IgG4                      **51 453**   **233 745**                                             **1.94 (1.49, 2.52)**   **\<.001**              
  Total IgG4/total IgE ratio      **52.16**    **75.24**                                               **1.36 (1.11, 1.67)**   **.005**                
  Total IgE/cockroach IgE ratio   **3.79**     **12.60**                                               **1.32 (1.06, 1.66)**   **.014**                
  Total IgE/dust mite IgE ratio   **0.562**    **1.301**                                               **1.13 (1.02, 1.25)**   **.016**                

                                              *Cockroach SPT−*   *Cockroach SPT+*                                
  ------------------------------- ----------- ------------------ ----------------------- ----------------------- ------------
  SWA                             IgE         1704               1894                    1.12 (0.94, 1.32)       .173
  IgG4                            12 860      14 155             1.04 (0.85, 1.28)       .675                    
  SEA                             IgE         1611               1876                    1.12 (0.97, 1.29)       .092
  IgG4                            84 831      101 778            1.08 (0.92, 1.27)       .319                    
  Dust mite                       IgE         **2.6**            **42.2**                **1.59 (1.35, 1.89)**   **\<.001**
  IgG4                            0.022       0.061              1.06 (0.87, 1.29)       .498                    
  IgG4/IgE ratio                  **0.009**   **0.001**          **0.56 (0.36, 0.85)**   **.010**                
  Cockroach                       IgE         **18.9**           **39.1**                **1.25 (1.08, 1.46)**   **.004**
  IgG4                            **0.054**   **0.686**          1.15 (0.95, 1.39)       .129                    
  IgG4/IgE ratio                  0.003       0.017              0.69 (0.47, 1.02)       .064                    
  Total IgE                       **1462**    **2787**           **1.22 (1.05, 1.42)**   **.011**                
  Total IgG4                      90 643      126 688            0.84 (0.65, 1.07)       .163                    
  Total IgG4/total IgE ratio      **60.41**   **45.80**          **0.75 (0.58, 0.95)**   **.022**                
  Total IgE/cockroach IgE ratio   6.07        9.22               1.01 (0.82, 1.25)       .894                    
  Total IgE/dust mite IgE ratio   0.849       0.868              0.93 (0.84, 1.03)       .140                    

                                              *Dust mite SPT−*   *Dust mite SPT+*                                
  ------------------------------- ----------- ------------------ ----------------------- ----------------------- ------------
  SWA                             IgE         **1667**           **2409**                **1.26 (1.00, 1.57)**   **.043**
  IgG4                            13 088      12 565             1.04 (0.79, 1.36)       .744                    
  SEA                             IgE         **1623**           **1887**                **1.23 (0.99, 1.53)**   **.055**
  IgG4                            85 471      102 026            1.20 (0.85, 1.68)       .271                    
  Dust mite                       IgE         **2.5**            **242.9**               **2.10 (1.57, 2.81)**   **\<.001**
  IgG4                            **0.020**   **0.245**          **1.41 (0.99, 1.99)**   **.052**                
  IgG4/IgE ratio                  0.009       0.001              0.49 (0.23, 1.04)       .064                    
  Cockroach                       IgE         **19.9**           **33.7**                **1.21 (1.03, 1.43)**   **.024**
  IgG4                            0.065       0.405              1.13 (0.85, 1.50)       .395                    
  IgG4/IgE ratio                  0.004       0.013              0.71 (0.48, 1.04)       .075                    
  Total IgE                       **1533**    **2802**           **1.24 (1.03, 1.49)**   **.025**                
  Total IgG4                      89 885      156 204            1.09 (0.86, 1.38)       .438                    
  Total IgG4/total IgE ratio      57.43       55.45              0.89 (0.72, 1.11)       .292                    
  Total IgE/cockroach IgE ratio   6.41        8.11               1.01 (0.82, 1.26)       .893                    
  Total IgE/dust mite IgE ratio   **0.937**   **0.517**          **0.81 (0.74, 0.89)**   **\<.001**              

                                              *No wheeze*   *Wheeze*                                        
  ------------------------------- ----------- ------------- ----------------------- ----------------------- ----------
  SWA                             IgE         1672          2627                    1.15 (0.81, 1.64)       .425
  IgG4                            12 753      14 802        1.05 (0.71, 1.54)       .808                    
  SEA                             IgE         1636          1547                    0.93 (0.66, 1.29)       .662
  IgG4                            81 698      145 978       1.16 (0.77, 1.73)       .449                    
  House dust mite                 IgE         2.8           26.6                    1.35 (0.89, 2.04)       .148
  IgG4                            0.007       0.008         0.85 (0.59, 1.25)       .407                    
  IgG4/IgE ratio                  **0.011**   **0.001**     **0.45 (0.22, 0.93)**   **.032**                
  Cockroach                       IgE         **21.2**      **2.9**                 **0.69 (0.55, 0.87)**   **.003**
  IgG4                            **0.021**   **0.006**     **0.65 (0.53, 0.82)**   **.001**                
  IgG4/IgE ratio                  0.004       0.002         1.14 (0.47, 2.74)       .760                    
  Total IgE                       1630        1522          0.88 (0.72, 1.07)       .205                    
  Total IgG4                      100 983     74 475        0.85 (0.61, 1.17)       .302                    
  Total IgG4/total IgE ratio      61.00       47.36         0.95 (0.77, 1.18)       .683                    
  Total IgE/cockroach IgE ratio   6.29        6.86          0.91 (0.78, 1.05)       .187                    
  Total IgE/dust mite IgE ratio   0.857       0.752         0.91 (0.77, 1.05)       .188                    

SWA, *Schistosoma* worm antigen; SEA, *Schistosoma* egg antigen; SmKK*−*, Kato‐Katz negative result (*S. mansoni*), single stool sample; SmKK+, Kato‐Katz positive result, single stool sample; aGMR, adjusted geometric mean ratio; 95% CI, 95% confidence interval. *P* values ≤0.05 are highlighted in bold.

All antibody concentrations in ng/mL.

All geometric mean ratios and 95% confidence intervals adjusted for survey design, age and sex.

Geometric mean ratios and 95% confidence intervals for associations between antibody levels and SPT reactivity and wheeze were additionally adjusted for SmKK result.

John Wiley & Sons, Ltd

Kato‐Katz positivity was also strongly positively associated with total IgE (*P* \< .001) (Table [3](#pim12506-tbl-0003){ref-type="table-wrap"} and Figure [S1](#pim12506-sup-0001){ref-type="supplementary-material"}), which was in turn weakly correlated with SEA‐specific IgE but moderately correlated with SWA‐specific IgE (*r* ~s~ = .31 and *r* ~s~ = .51, respectively; Table [S2](#pim12506-sup-0001){ref-type="supplementary-material"}). Similarly, total IgG4 (*P* \< .001), total IgG4/total IgE ratios (*P* = .005) and total IgE/asIgE ratios (*P* \< .05) were positively associated with Kato‐Katz positivity. In addition, there was a general dose‐response relationship between *S. mansoni* infection intensity and antibody responses (Table [S3](#pim12506-sup-0001){ref-type="supplementary-material"}B).

Cockroach‐specific IgE and total IgE were positively associated with cockroach SPT reactivity. HDM‐specific IgE and IgG4, SWA‐ and SEA‐specific IgE and total IgE, were all positively associated with HDM SPT reactivity (Table [3](#pim12506-tbl-0003){ref-type="table-wrap"} and Figure [S1](#pim12506-sup-0001){ref-type="supplementary-material"} **)**. In contrast, cockroach SPT reactivity was inversely associated with total IgG4/total IgE ratios (*P* = .022), and HDM SPT reactivity with total IgE/HDM‐specific IgE ratios (*P* \< .001).

Associations between wheeze and antibody responses (Table [3](#pim12506-tbl-0003){ref-type="table-wrap"} and Figure [S1](#pim12506-sup-0001){ref-type="supplementary-material"}), when significant, were inverse. HDM IgG4/IgE ratios (*P* = .032), cockroach‐specific IgE (*P* = .003) and cockroach‐specific IgG4 (*P* = .001) were all inversely associated with wheeze.

4. DISCUSSION {#pim12506-sec-0009}
=============

In this highly *Sm*‐endemic setting, associations between wheeze and *Sm*‐specific cytokines and antibodies, when significant, were inverse. However, SPT reactivity and detectable asIgE were positively associated with the same *Sm*‐specific responses.

In this population, *Sm* exposure is almost universal, and infection much higher than indicated by Kato‐Katz: urine assessment for *Sm* circulating cathodic antigen (CCA) indicated a prevalence of over 70%, compared to 51.4% prevalence by Kato‐Katz.[22](#pim12506-bib-0022){ref-type="ref"} Therefore, Kato‐Katz negativity in many study participants was indicative of lighter (rather than absent) infection. This explains why, although SWA‐specific Th2‐type and regulatory cytokine responses were generally higher among SmKK+ individuals, only SWA‐specific IL‐5 reached significant levels, and why SEA‐specific responses were similar between SmKK+ and SmKK‐ individuals. Further support for these observations comes from supplementary analysis (Table [S4](#pim12506-sup-0001){ref-type="supplementary-material"}A), which shows that cytokine responses were similar between SmKK‐CCA+ and SmKK+CCA± individuals.

All statistically significant associations between atopy and *Sm*‐specific cytokine responses were positive. Associations with whole blood cytokine responses are best interpreted taking into account total cell counts, but these data were unavailable. However, atopy‐antibody associations were also positive. Besides, these results mirror our previous epidemiological observations in this population, where *Sm* infection was positively associated with *Dermatophagoides*‐specific IgE, and atopy‐wheeze associations were stronger in the presence of *Sm* infection.[21](#pim12506-bib-0021){ref-type="ref"}

Our results were unexpected in view of earlier findings from Gabon[9](#pim12506-bib-0009){ref-type="ref"} which showed an inverse association between dust mite SPT and SWA‐specific IL‐10 (albeit we used whole blood cultures, compared to peripheral blood mononuclear cells in the Gabon study). However, although IL‐10 is chiefly immunomodulatory,[26](#pim12506-bib-0026){ref-type="ref"}, [27](#pim12506-bib-0027){ref-type="ref"}, [28](#pim12506-bib-0028){ref-type="ref"} it may also enhance IgE production in already IgE‐switched B cells;[13](#pim12506-bib-0013){ref-type="ref"} these may be abundant in individuals from this helminth‐endemic setting. SWA‐ and SEA‐specific IgE were weakly positively associated with HDM SPT reactivity, perhaps unsurprisingly, as helminth antigens may induce cross‐reactive helminth‐ and allergen‐specific IgE effector responses. Total serum IgE, elevated during helminth infection mainly due to increased synthesis of polyclonal IgE, has been proposed to inhibit allergic responses.[29](#pim12506-bib-0029){ref-type="ref"}, [30](#pim12506-bib-0030){ref-type="ref"} However, contrasting evidence links high serum IgE levels to increased expression of IgE receptors on human basophils,[31](#pim12506-bib-0031){ref-type="ref"} and we show positive associations between total IgE and SPT reactivity to both cockroach and dust mite.

In keeping with the original hypothesis, associations between wheeze and cytokine and antibody responses, when significant, were inverse. Furthermore, total and allergen‐specific IgG4/IgE ratios were mostly inversely associated with atopy, implying that the regulatory role of IgG4 against allergy might best be assessed relative to IgE. Also, lower total/asIgE ratios among HDM SPT+ individuals are consistent with the perception that high total/asIgE ratios may be protective against allergic responses, because nonspecific polyclonal IgE may compete with asIgE to saturate IgE receptors.[29](#pim12506-bib-0029){ref-type="ref"}

One limitation of assessing helminth‐allergy associations and underlying mechanisms in this population is the almost universal exposure to helminths, and lack of data on duration of infection. We also report a large number of statistical tests, so some apparently "significant" findings could have occurred by chance. As we anticipated that some of our measures might be correlated, we did not formally adjust for multiplicity, instead we focussed on patterns of association and consistency of results, and on biological plausibility with reference to other findings. Another potential limitation is that wheeze was relatively rare in the study population, and hence, some of our comparison groups (such as the age group 1‐17 years) had a low prevalence. Besides, reported wheeze could easily be misclassified in this population due to lack of a direct translation of "wheeze" in the native languages.[21](#pim12506-bib-0021){ref-type="ref"}

Nonetheless, our results generally agree with our epidemiological observations in the same population,[21](#pim12506-bib-0021){ref-type="ref"} where we found a very low prevalence of clinical allergies, despite positive helminth‐atopy associations.
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